Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative SOX Combined H. Pylori Eradication in Locally Advanced Gastric Cancer
NCT06510010Phase 2Recruiting
- Sponsor
- The Sixth Affiliated Hospital of Sun Yat-Sen University
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of amoxicillin, clarithromycin, omeprazole and bismuth subcitrate in gastric cancer (GC), oesophagogastric junction cancer (OGJ) and Helicobacter pylori infection (2 arms), sponsored by The Sixth Affiliated Hospital of Sun Yat-Sen University. Primary endpoint: Major Pathological Response. Started Dec 2024; status: recruiting.
02
Drugs
amoxicillinclarithromycinomeprazolebismuth subcitrate
03
Conditions
gastric cancer (GC)oesophagogastric junction cancer (OGJ)Helicobacter pylori infection
Beyond the preview
Go deeper on NCT06510010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06510010.